BIOMARIN PHARMACEUTICAL INC (BMRN) Stock Fundamental Analysis
NASDAQ:BMRN - Nasdaq - US09061G1013 - Common Stock - Currency: USD
Taking everything into account, BMRN scores 6 out of 10 in our fundamental rating. BMRN was compared to 559 industry peers in the Biotechnology industry. BMRN has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. A decent growth rate in combination with a cheap valuation! Better keep an eye on BMRN. With these ratings, BMRN could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year BMRN was profitable.
In the past year BMRN had a positive cash flow from operations.
Of the past 5 years BMRN 4 years were profitable.
Each year in the past 5 years BMRN had a positive operating cash flow.
1.2 Ratios
BMRN has a Return On Assets of 7.33%. This is amongst the best in the industry. BMRN outperforms 93.38% of its industry peers.
BMRN has a better Return On Equity (9.04%) than 93.92% of its industry peers.
BMRN has a better Return On Invested Capital (9.16%) than 94.63% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for BMRN is significantly below the industry average of 14.78%.
The 3 year average ROIC (3.73%) for BMRN is below the current ROIC(9.16%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| ROIC | 9.16% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
1.3 Margins
The Profit Margin of BMRN (17.76%) is better than 95.17% of its industry peers.
With an excellent Operating Margin value of 24.13%, BMRN belongs to the best of the industry, outperforming 96.42% of the companies in the same industry.
The Gross Margin of BMRN (79.44%) is better than 85.15% of its industry peers.
In the last couple of years the Gross Margin of BMRN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.13% | ||
| PM (TTM) | 17.76% | ||
| GM | 79.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BMRN is destroying value.
The number of shares outstanding for BMRN has been increased compared to 1 year ago.
Compared to 5 years ago, BMRN has more shares outstanding
Compared to 1 year ago, BMRN has an improved debt to assets ratio.
2.2 Solvency
BMRN has an Altman-Z score of 6.10. This indicates that BMRN is financially healthy and has little risk of bankruptcy at the moment.
BMRN has a better Altman-Z score (6.10) than 80.32% of its industry peers.
The Debt to FCF ratio of BMRN is 0.96, which is an excellent value as it means it would take BMRN, only 0.96 years of fcf income to pay off all of its debts.
BMRN's Debt to FCF ratio of 0.96 is amongst the best of the industry. BMRN outperforms 94.99% of its industry peers.
A Debt/Equity ratio of 0.10 indicates that BMRN is not too dependend on debt financing.
BMRN's Debt to Equity ratio of 0.10 is on the low side compared to the rest of the industry. BMRN is outperformed by 65.47% of its industry peers.
Although BMRN does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.96 | ||
| Altman-Z | 6.1 |
ROIC/WACC0.98
WACC9.31%
2.3 Liquidity
A Current Ratio of 5.52 indicates that BMRN has no problem at all paying its short term obligations.
BMRN's Current ratio of 5.52 is in line compared to the rest of the industry. BMRN outperforms 56.89% of its industry peers.
A Quick Ratio of 3.49 indicates that BMRN has no problem at all paying its short term obligations.
BMRN has a Quick ratio (3.49) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.52 | ||
| Quick Ratio | 3.49 |
3. Growth
3.1 Past
BMRN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 136.84%, which is quite impressive.
Looking at the last year, BMRN shows a quite strong growth in Revenue. The Revenue has grown by 19.36% in the last year.
Measured over the past years, BMRN shows a quite strong growth in Revenue. The Revenue has been growing by 10.86% on average per year.
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
3.2 Future
Based on estimates for the next years, BMRN will show a very strong growth in Earnings Per Share. The EPS will grow by 28.03% on average per year.
BMRN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 7.68% yearly.
EPS Next Y56.4%
EPS Next 2Y41.9%
EPS Next 3Y33%
EPS Next 5Y28.03%
Revenue Next Year11.37%
Revenue Next 2Y10.68%
Revenue Next 3Y9.93%
Revenue Next 5Y7.68%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BMRN is valuated rather expensively with a Price/Earnings ratio of 21.17.
Compared to the rest of the industry, the Price/Earnings ratio of BMRN indicates a rather cheap valuation: BMRN is cheaper than 94.99% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of BMRN to the average of the S&P500 Index (26.59), we can say BMRN is valued slightly cheaper.
BMRN is valuated correctly with a Price/Forward Earnings ratio of 12.85.
BMRN's Price/Forward Earnings ratio is rather cheap when compared to the industry. BMRN is cheaper than 95.35% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of BMRN to the average of the S&P500 Index (22.39), we can say BMRN is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.17 | ||
| Fwd PE | 12.85 |
4.2 Price Multiples
96.06% of the companies in the same industry are more expensive than BMRN, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, BMRN is valued cheaply inside the industry as 94.63% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.68 | ||
| EV/EBITDA | 12.6 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
BMRN has a very decent profitability rating, which may justify a higher PE ratio.
BMRN's earnings are expected to grow with 33.00% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.38
PEG (5Y)N/A
EPS Next 2Y41.9%
EPS Next 3Y33%
5. Dividend
5.1 Amount
No dividends for BMRN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
57.16
-0.32 (-0.56%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners98.66%
Inst Owner Change0.92%
Ins Owners0.69%
Ins Owner Change8.7%
Market Cap10.96B
Analysts82.86
Price Target97.86 (71.2%)
Short Float %2.34%
Short Ratio2.18
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.95%
Min EPS beat(2)18.43%
Max EPS beat(2)31.48%
EPS beat(4)4
Avg EPS beat(4)27.84%
Min EPS beat(4)4.22%
Max EPS beat(4)57.23%
EPS beat(8)6
Avg EPS beat(8)15.96%
EPS beat(12)9
Avg EPS beat(12)-4.68%
EPS beat(16)13
Avg EPS beat(16)7.99%
Revenue beat(2)1
Avg Revenue beat(2)0.66%
Min Revenue beat(2)-1.37%
Max Revenue beat(2)2.69%
Revenue beat(4)3
Avg Revenue beat(4)2.79%
Min Revenue beat(4)-1.37%
Max Revenue beat(4)5.44%
Revenue beat(8)3
Avg Revenue beat(8)-0.01%
Revenue beat(12)5
Avg Revenue beat(12)-0.3%
Revenue beat(16)7
Avg Revenue beat(16)-0.11%
PT rev (1m)-0.12%
PT rev (3m)-1.36%
EPS NQ rev (1m)6.19%
EPS NQ rev (3m)12.04%
EPS NY rev (1m)5.89%
EPS NY rev (3m)11.64%
Revenue NQ rev (1m)-0.17%
Revenue NQ rev (3m)-1.01%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 21.17 | ||
| Fwd PE | 12.85 | ||
| P/S | 3.72 | ||
| P/FCF | 17.68 | ||
| P/OCF | 15.65 | ||
| P/B | 1.89 | ||
| P/tB | 2.05 | ||
| EV/EBITDA | 12.6 |
EPS(TTM)2.7
EY4.72%
EPS(NY)4.45
Fwd EY7.78%
FCF(TTM)3.23
FCFY5.66%
OCF(TTM)3.65
OCFY6.39%
SpS15.38
BVpS30.21
TBVpS27.9
PEG (NY)0.38
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.33% | ||
| ROE | 9.04% | ||
| ROCE | 10.92% | ||
| ROIC | 9.16% | ||
| ROICexc | 11.38% | ||
| ROICexgc | 12.43% | ||
| OM | 24.13% | ||
| PM (TTM) | 17.76% | ||
| GM | 79.44% | ||
| FCFM | 21.02% |
ROA(3y)3.59%
ROA(5y)4.88%
ROE(3y)4.67%
ROE(5y)6.69%
ROIC(3y)3.73%
ROIC(5y)N/A
ROICexc(3y)4.34%
ROICexc(5y)N/A
ROICexgc(3y)4.77%
ROICexgc(5y)N/A
ROCE(3y)4.44%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.25%
GM growth 5Y0.19%
F-Score8
Asset Turnover0.41
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.1 | ||
| Debt/FCF | 0.96 | ||
| Debt/EBITDA | 0.74 | ||
| Cap/Depr | 87.86% | ||
| Cap/Sales | 2.71% | ||
| Interest Coverage | 79.64 | ||
| Cash Conversion | 87.19% | ||
| Profit Quality | 118.38% | ||
| Current Ratio | 5.52 | ||
| Quick Ratio | 3.49 | ||
| Altman-Z | 6.1 |
F-Score8
WACC9.31%
ROIC/WACC0.98
Cap/Depr(3y)111.01%
Cap/Depr(5y)114.82%
Cap/Sales(3y)4.71%
Cap/Sales(5y)5.6%
Profit Quality(3y)57.85%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)136.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%106.52%
EPS Next Y56.4%
EPS Next 2Y41.9%
EPS Next 3Y33%
EPS Next 5Y28.03%
Revenue 1Y (TTM)19.36%
Revenue growth 3Y15.62%
Revenue growth 5Y10.86%
Sales Q2Q%14.84%
Revenue Next Year11.37%
Revenue Next 2Y10.68%
Revenue Next 3Y9.93%
Revenue Next 5Y7.68%
EBIT growth 1Y301.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year102.12%
EBIT Next 3Y41.83%
EBIT Next 5Y23.16%
FCF growth 1Y2744.87%
FCF growth 3Y36.9%
FCF growth 5YN/A
OCF growth 1Y375.08%
OCF growth 3Y23.45%
OCF growth 5Y63.99%